Pfizer to launch series of products under Corex brand

Pfizer will be launching a series of products as line extensions under the Corex brand, starting with the first launch in December, 2016 and subsequent launches over the next year. The company has also decided to discontinue the manufacture of the current Corex cough syrup formulation (Codeine Phosphate 10mg + Chlorpheniramine Maleate 4mg).

Pfizer has undertaken a comprehensive review of its respiratory offerings to better cover a broader range of indications through an expanded product portfolio. The company will launch additional products while it may also discontinue the manufacture of certain SKUs where needed.

Pfizer plans to provide more comprehensive set of solutions in respiratory indications, while ensuring minimal impact towards patients resulting from the discontinuation of manufacturing of the current Corex cough syrup formulation. Corex cough syrup recorded a sale of Rs 244.48 crore in FY16.

On the financial front, Pfizer’s revenue increased 4.79 per cent to Rs 536 crore in Q2FY17 on a yearly basis. The company’s PAT also increased to Rs 126 crore in Q2FY17 as compared to the same period in the previous fiscal year.

The share price of Pfizer increased 2.16 per cent on the bourses in early trades and is trading at Rs 1837.95 on intraday basis.